1. Home
  2. XERS vs SBC Comparison

XERS vs SBC Comparison

Compare XERS & SBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XERS
  • SBC
  • Stock Information
  • Founded
  • XERS 2005
  • SBC 2000
  • Country
  • XERS United States
  • SBC United States
  • Employees
  • XERS N/A
  • SBC N/A
  • Industry
  • XERS Biotechnology: Pharmaceutical Preparations
  • SBC
  • Sector
  • XERS Health Care
  • SBC
  • Exchange
  • XERS Nasdaq
  • SBC NYSE
  • Market Cap
  • XERS 526.3M
  • SBC 525.5M
  • IPO Year
  • XERS 2018
  • SBC N/A
  • Fundamental
  • Price
  • XERS $4.24
  • SBC $3.28
  • Analyst Decision
  • XERS Strong Buy
  • SBC
  • Analyst Count
  • XERS 4
  • SBC 0
  • Target Price
  • XERS $5.75
  • SBC N/A
  • AVG Volume (30 Days)
  • XERS 2.4M
  • SBC 48.6K
  • Earning Date
  • XERS 03-06-2025
  • SBC 03-18-2025
  • Dividend Yield
  • XERS N/A
  • SBC N/A
  • EPS Growth
  • XERS N/A
  • SBC 737.76
  • EPS
  • XERS N/A
  • SBC 6.66
  • Revenue
  • XERS $203,070,000.00
  • SBC $223,344,699.00
  • Revenue This Year
  • XERS $20.47
  • SBC $14.23
  • Revenue Next Year
  • XERS $19.35
  • SBC $16.70
  • P/E Ratio
  • XERS N/A
  • SBC $0.49
  • Revenue Growth
  • XERS 23.89
  • SBC 28.24
  • 52 Week Low
  • XERS $1.69
  • SBC $2.62
  • 52 Week High
  • XERS $4.50
  • SBC $36.52
  • Technical
  • Relative Strength Index (RSI)
  • XERS 70.54
  • SBC N/A
  • Support Level
  • XERS $3.59
  • SBC N/A
  • Resistance Level
  • XERS $4.50
  • SBC N/A
  • Average True Range (ATR)
  • XERS 0.25
  • SBC 0.00
  • MACD
  • XERS 0.03
  • SBC 0.00
  • Stochastic Oscillator
  • XERS 72.34
  • SBC 0.00

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.

About SBC SBC MEDICAL GROUP HOLDINGS INCRPRTD

SBC Medical Group Holdings Inc is a management company that provides management services to cosmetic treatment centers mainly in Japan. It is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumables procurement (resale). They provide management services to a total of One hundred fifty eight franchisee treatment centers under the brand name Shonan Beauty Clinic located in Japan.

Share on Social Networks: